Fibrinolytic enzymes are vital in the breakdown of blood clots, and the complex pathway of their activation involves several key components including tissue plasminogen activator (tPA), plasminogen, and plasmin. These molecules play a crucial role in maintaining vascular homeostasis and preventing thrombosis. The tPA, for example, activates plasminogen to generate active plasmin, which in turn degrades fibrin clots. This cascade of events is crucial for preventing excessive clotting and maintaining proper blood flow. Moreover, the dysregulation of this system can lead to various pathological conditions such as myocardial infarction and stroke. Therefore, understanding the intricate interactions between fibrinolytic enzymes and their activators is of great importance in the field of medicine and biomedical research. A comprehensive understanding of these processes is critical for the development of novel therapeutic interventions to modulate fibrinolysis and treat clot-related disorders.
纤溶酶原激活因子,Plasminogen activator
1)Plasminogen activator纤溶酶原激活因子
1.Expressions of plasminogen activators and inhibitors in mice during reproductive cycle;小鼠生殖周期中纤溶酶原激活因子及抑制因子的表达
2.Plasminogen activators include urokinase type(uPA) and tissue type(tPA) plasminogen activator,which play a critical role in promoting proteolysis of extracellular matrix.纤溶酶原激活因子(PA)包括尿激酶型(uPA)及组织型(tPA),在诱发细胞外基质蛋白水解中起重要作用。
3.Researches on the mechanism of semen delayed liquefaction resulting from CP mainly focus on the proteolytic ferment,plasminogen activator,prostate acid phosphatase,tissue factor,lack of zinc,and pH.目前对CP所致精液延迟液化机制的研究主要集中在蛋白水解酶系、纤溶酶原激活因子系统和微量元素锌缺乏以及pH值改变等方面。
英文短句/例句
1.Cloning and Expression of Urokinase Type Plasminogen Activator cDNA尿激酶型纤溶酶原激活因子cDNA的克隆与原核表达
2.The Study on Relationship between the Expression of Plasminogen Activator, Plasminogen Activator Inhibitors and Invasion and Metastasis in Ovarian Carcinoma;纤溶酶原激活因子及其抑制因子与卵巢癌的浸润转移
3.Study of the Urokinase-type Plasminogen Activator Inhibited by Triplex-Forming Oligonucleotides in Rat Sertoli Cells;三链形成寡核苷酸对大鼠Sertoli细胞尿激酶型纤溶酶原激活因子的反基因研究
4.Study of the Roles and Mechanisms of Urokinase-type Plasminogen Activator in Promoting Male Fertility;尿激酶型纤溶酶原激活因子多环节促雄性生育作用及相关机制探讨实验研究
5.The invasion and metastasis of epithelial ovarian cancer be mediated by urokinase-type plasminogen activator in vitro尿激酶型纤溶酶原激活因子介导的卵巢上皮癌细胞浸润转移体外的实验研究
6.Expression of Plasminogen Activator、Plasminogen Activator Inhibitor in Polycystic Ovary Syndrome纤溶酶原激活、抑制因子在PCOS卵巢中的表达
7.Clinical Study of the Expression of Tissue Factor and Urokinase Plasminogen Activator Receptor in Breast Cancer组织因子、尿激酶型纤溶酶原激活剂受体在乳腺癌中的表达
8.The expression of plasminogen activator inhibitor 1 (PAI 1) gene in human astrocytomasG人脑星形细胞瘤纤溶酶原激活抑制因子1基因表达研究
9.Treatment of Experimental Hepatic Fibrosis by Combination of Urokinase-type Plasminogen Activator and Hepatocyte Growth Factor Gene Delivery;尿激酶型纤溶酶原激活剂和肝细胞生长因子联合基因治疗实验性肝纤维化
10.Cytokine-induced release of plasminogen activator inhibitor-1 by human pleural mesothelial cells细胞因子诱导人胸膜细胞释放纤溶酶原激活物抑制剂-1的研究
11.Epidermal growth factor differently modulate activity of urokinase plasminogen activator and plasminogen ac-tivator inhibitor-1 in oral squamous cell carcinoma and metastasis carcinoma cell lines外源性表皮生长因子对口腔鳞癌细胞系尿激酶型纤溶酶原激活剂及其抑制剂活性的影响
12.Expression and Prognostic Significance of Nuclear Factor-kappaBp-65 and uPA in Cervical Carcinoma;核转录因子-kBp65和尿激酶型纤溶酶原激活剂在人宫颈癌中的表达及预后意义
parison of Recombinant Tissue Plasminogen Activator, Urokinase and Defibrase in Vitro Simulation of Thrombolytic Test重组织型纤溶酶原激活剂、尿激酶和降纤酶体外溶栓效果比较
14.Association of plasminogen activator inhibitor-1 gene promoter 4G/5G genotype polymorphism with gestational diabetes纤溶酶原激活物抑制因子1基因启动子区4G/5G多态性与妊娠糖尿病的相关性研究
15.The Changes of the Plasiminogen Activitor Inhibitor-1(PAI-1) in Patients with Coronary Heart Desease and It s Relationship to Clinical Factors;冠心病患者血浆纤溶酶原激活剂抑制因子（PAI-1）的变化及其相关因素的研究
16.Study on Recombinant Nonglycosylated Urokinase-type Plasminogen Activator;重组非糖基化尿激酶型纤溶酶原激活剂的研究
17.recombinant human plasminogen重组体人纤溶酶原激活质
18.Establishment of Transgenic Goats for Human Tissue-type Plasminogen Activator with Sperm Mediated Gene Transfer Method;利用精子载体方法研制人组织型纤溶酶原激活剂突变体转基因羊乳腺生物反应器
相关短句/例句
plasminogen activator尿型纤溶酶原激活因子
1.The relationship between the expression ofplasminogen activator,plasminogen activator inhibitors and invasion and metastasis in ovarian carcinoma;尿型纤溶酶原激活因子及其1型抑制因子mRNA表达与卵巢癌临床病理及预后的关系
2.Objective:To explore the clinical-pathologic parameters on expression ofplasminogen activator(uPA),plasminogen activator inhibitors(PAI-1) in ovarian cancer.目的:探讨卵巢恶性肿瘤组织中尿型纤溶酶原激活因子(uPA)及其1型抑制因子(PAI-1)表达的临床意义。
3)urokinase-type plasminogen activator尿激酶型纤溶酶原激活因子
1.Objective:To investigate the effects ofurokinase-type plasminogen activator(uPA) on the reproductive function of the male rats with ornidazole-induced infertility.目的:探讨尿激酶型纤溶酶原激活因子(uPA)对于奥硝唑所致的雄性不育大鼠生育力的影响。
2.Objective: To study the effects of theurokinase-type plasminogen activator (uPA) on the chemotactic responses of spermatozoa in vitro, and to explore the possible action mechanisms of uPA for male infertility.目的:研究尿激酶型纤溶酶原激活因子(uPA)是否能诱导精子产生趋化性运动,从而探讨uPA在治疗男性不育中的可能作用机制。
4)urokinasetype plasminogen activator(uPA)尿激酶纤溶酶原激活因子(uPA)
5)urokinase type plasminogen activator尿激酶型纤溶酶原激活因子
1.ObjectiveThe experimental study was aimed to investigate the change and its clinical significance ofurokinase type plasminogen activator (uPA) levels in patients with primary hepatocellular carcinoma (HCC) before and after the interventional therapy by detected the level of uPA in patients with HCC before and after the treatment.目的通过检测原发性肝癌患者介入治疗前后血清中尿激酶型纤溶酶原激活因子(urokinase type plasminogen activator,uPA)的含量,探讨uPA在原发性肝癌介入治疗前后的表达变化及其临床意义。
6)Inhibitor of plasminogen activator纤溶酶原激活因子的抑制因子
延伸阅读
纤溶酶原激活剂分子式：CAS号：性质：是一组蛋白酶，使纤溶酶激活生成有活性的纤溶酶。它们主要包括：(1)组织纤溶酶激动剂(tPA)，一种丝氨酸蛋白酶，创伤或应激时从血管内皮释放入血，只有同纤维蛋白结合时才有激活纤溶酶原的活性；(2)尿激酶，对纤维蛋白选择性较低，是某些内皮细胞系合成、经外分泌管道(如肾小管)分泌，可能参与清除沉积在管道内的纤维蛋白；(3)链激酶，临床上用于裂解纤维蛋白，其选择性较差，可作用于液相中的纤溶酶原，也可作用于纤维蛋白血块中的纤溶酶原，链激酶不是蛋白酶，但与纤溶酶原结合成复合物后构象改变，显示蛋白水解酶活性。
